Skip to main content
OpenTrials

Clinical trial condition

HER2-Positive Metastatic Breast Cancer

Explore clinical trials studying HER2-Positive Metastatic Breast Cancer. Study availability and eligibility vary by location and protocol.

19 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

HER2-Positive Metastatic Breast Cancer trial results

Recruiting

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

NCT06551116

Conditions
HER2-Positive Metastatic Breast Cancer
Locations
  • University of California San Francisco Medical Center San Francisco, California, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center Fairfield, Connecticut, United States
  • Smilow Cancer Hospital at Glastonbury Glastonbury, Connecticut, United States
View all 37 locations
View Trial Details
Recruiting

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

NCT06595563

Conditions
HER2-Positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer
Locations
  • Institut Jules Bordet Anderlecht, Brussels Capital, Belgium
  • CHU Charleroi - Marie Curie Charleroi, Belgium
  • UZ Gent Ghent, Belgium
  • UZ Leuven Leuven, Belgium
View Trial Details
Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Conditions
Advanced Breast Cancer, Advanced Lung Cancer, Breast Diseases, +35 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • University of California San Diego Moores Cancer Center San Diego, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
View all 40 locations
View Trial Details
Recruiting

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

NCT05800275

Conditions
Central Nervous System Neoplasms, HER2-Positive Metastatic Breast Cancer, Leptomeningeal Disease, +7 more
Locations
  • Institut Bergonié Bordeaux, France
  • Centre François Baclesse Caen, France
  • Centre Jean Perrin Clermont-Ferrand, France
  • Centre Georges-François Leclerc Dijon, France
View Trial Details
Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program

NCT05868226

Conditions
Breast Diseases, Breast Neoplasms, ER Positive Breast Cancer, +29 more
Locations
  • The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Birmingham, Alabama, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • The University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States
  • UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital New Lenox, Illinois, United States
View Trial Details

Related conditions